Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kevin DeGeeter
LT
Kevin DeGeeter
Ladenburg Thalmann & Co.
Wall Street Analyst
★☆☆☆☆
#2536
on 13Foresight · ranked by our own returns
35%
Success Rate
-11.5%
Average Return
15 of 43 calls profitable · -16.1% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 35% of Kevin DeGeeter's ratings turned a profit when each position was held for 1 year — averaging -11.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

13 Buy 1 Hold 0 Sell
Kevin's Stock Coverage 53 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ELTX
Elicio Therapeutics
 Jun 18, 2026 BUY Buy
+393.5% avg upside
11 analysts
$12.00
211.65% Upside
 ·
TRAW
Traws Pharma
 Jun 15, 2026 HOLD Buy
+3604.6% avg upside
10 analysts
 — ·
CLRB
Cellectar Biosciences
 May 15, 2026 BUY Strong Buy
+2960.9% avg upside
7 analysts
$10.00
258.36% Upside
 -19.7%
URGN
Urogen Pharma
 May 11, 2026 BUY Strong Buy
+13.0% avg upside
16 analysts
$43.00
28.10% Upside
 +4.7%
DCOY
Decoy Therapeutics
 Jan 23, 2026 BUY Strong Buy
+338.9% avg upside
7 analysts
$2.50
58.80% Downside
 -38.0%
ORIC
Oric Pharmaceuticals
 Nov 14, 2025 BUY Strong Buy
+180.3% avg upside
19 analysts
$15.00
76.68% Upside
 -32.5%
CRDF
Cardiff Oncology
 Nov 10, 2025 BUY Strong Buy
+732.8% avg upside
18 analysts
$19.00
1470.19% Upside
 -25.6%
NXTC
NextCure
 Nov 07, 2025 BUY Buy
+776.9% avg upside
10 analysts
$18.00
791.07% Upside
 +8.7%
OPK
Opko Health
 Oct 30, 2025 BUY Strong Buy
+374.2% avg upside
12 analysts
$3.00
111.26% Upside
 -22.6%
NVCR
NovoCure
 Jul 08, 2025 BUY Strong Buy
+242.4% avg upside
11 analysts
$30.00
110.00% Upside
 +0.4%
IONS
Ionis Pharmaceuticals
 Apr 19, 2022 BUY Strong Buy
+13.3% avg upside
43 analysts
$59.00
20.49% Downside
 -10.3%
ANTX
AN2 Therapeutics, Inc.
 Apr 19, 2022 BUY Buy
+75.0% avg upside
7 analysts
$22.00
340.09% Upside
 -40.4%
TSHA
Taysha Gene Therapies
 Apr 01, 2022 BUY Strong Buy
+102.5% avg upside
21 analysts
$37.00
476.24% Upside
 -87.4%
SERA
Sera Prognostics
 Mar 30, 2022 BUY Strong Buy
+325.6% avg upside
7 analysts
$17.00
871.35% Upside
 +2.7%
INFIQ
Infinity Pharmaceuticals
 Mar 30, 2022 BUY Buy
+647142757.1% avg upside
8 analysts
$7.00
699999899.96% Upside
 -84.1%
PSNL
Personalis
 Feb 25, 2022 BUY Strong Buy
+12.8% avg upside
11 analysts
$24.00
127.80% Upside
 +8.1%
FLGT
Fulgent Genetics
 Jan 25, 2022 BUY Buy
+142.6% avg upside
7 analysts
$125.00
594.54% Upside
 -48.0%
BNGO
BioNano Genomics
 Dec 27, 2021 BUY Strong Buy
+730.2% avg upside
9 analysts
$14.00
1128.03% Upside
 -57.4%
NMTRQ
9 Meters Biopharma
 Nov 16, 2021 BUY Buy
+3234374900.0% avg upside
11 analysts
$5.00
499999899.94% Upside
 ·
SPRO
Spero Therapeutics
 Oct 01, 2021 HOLD Buy
+501.5% avg upside
12 analysts
 — -88.6%
ALP
Alpha Compute
 Sep 20, 2021 BUY Strong Buy
+8018.9% avg upside
6 analysts
$30.00
11957.78% Upside
 ·
MDWD
Mediwound
 Jul 20, 2021 BUY Strong Buy
+51.7% avg upside
13 analysts
$7.00
50.78% Downside
 -60.5%
MBRX
Moleculin Biotech
 Jul 13, 2021 BUY Strong Buy
+603.1% avg upside
5 analysts
$18.00
524.96% Upside
 -52.5%
EVAX
Evaxion Biotech
 Jul 08, 2021 BUY Strong Buy
+313.1% avg upside
6 analysts
$18.00
490.16% Upside
 -63.9%
VCEL
Vericel
 Jun 30, 2021 HOLD Strong Buy
+13.9% avg upside
16 analysts
 — -52.0%
IDYA
IDEAYA Biosciences
 Jun 28, 2021 BUY Strong Buy
+55.2% avg upside
29 analysts
$25.00
20.03% Downside
 -38.4%
FTH
Faeth Therapeutics
 Jun 28, 2021 HOLD Strong Buy
+108.4% avg upside
11 analysts
 — ·
NTBLQ
Notable Labs
 Jun 16, 2021 BUY Buy
+809999900.0% avg upside
12 analysts
$5.50
549999900.00% Upside
 ·
RZLT
Rezolute
 May 26, 2021 BUY Strong Buy
+122.8% avg upside
13 analysts
$25.00
398.00% Upside
 -61.0%
BGMS
Bio Green Med Solution
 Apr 29, 2021 BUY Strong Buy
+1647.8% avg upside
7 analysts
$17.00
2142.48% Upside
 -73.7%
RCKT
Rocket Pharmaceuticals
 Mar 04, 2021 HOLD Buy
+393.7% avg upside
29 analysts
 — -70.6%
RCEL
Avita Medical
 Mar 04, 2021 HOLD Strong Buy
+154.7% avg upside
10 analysts
 — -55.4%
IDXG
Interpace Diagnostics Group
 Nov 25, 2020 HOLD Strong Buy
+617.5% avg upside
9 analysts
 — ·
NVAX
Novavax
 Jun 15, 2020 HOLD Buy
+154.1% avg upside
20 analysts
 — +266.3%
GYRE
Gyre Therapeutics
 Feb 24, 2020 HOLD Strong Buy
+212.0% avg upside
15 analysts
 — -5.0%
LCTX
Lineage Therap
 May 09, 2019 BUY Strong Buy
+342.7% avg upside
16 analysts
$3.00
147.91% Upside
 ·
CFRXQ
ContraFect
 Jul 10, 2018 BUY Buy
+10969999900.0% avg upside
10 analysts
$3.00
299999900.08% Upside
 ·
ADMA
ADMA Biologics
 Jun 13, 2018 BUY Strong Buy
+57.2% avg upside
15 analysts
$7.50
9.70% Downside
 -19.8%
MESO
Mesoblast
 Apr 10, 2017 BUY Strong Buy
+72.5% avg upside
14 analysts
$13.25
7.79% Downside
 -43.1%
VXRT
Vaxart
 Feb 14, 2017 HOLD Strong Buy
+1315.6% avg upside
8 analysts
 — +13.6%
MYGN
Myriad Genetics
 Feb 08, 2017 HOLD Hold
+313.3% avg upside
24 analysts
 — +97.5%
CDXS
Codexis
 Jan 04, 2017 BUY Strong Buy
+291.5% avg upside
13 analysts
 — +68.4%
TEVA
Teva Pharmaceutical
 Dec 15, 2014 HOLD Buy
-6.6% avg upside
39 analysts
 — +19.4%
BGMD
BG Medicine
 Nov 13, 2014 HOLD Hold
+299999899.9% avg upside
2 analysts
 — ·
GPRO
GoPro
 Oct 31, 2014 SELL Hold
+2641.8% avg upside
18 analysts
$45.00
5597.01% Upside
 +67.6%
INCY
Incyte
 Oct 30, 2014 BUY Buy
+1.0% avg upside
47 analysts
$75.00
23.70% Downside
 +83.1%
CRIS
Curis
 Aug 07, 2014 BUY Strong Buy
+1932.2% avg upside
12 analysts
$3.00
612.65% Upside
 +53.6%
AMGN
Amgen
 Apr 04, 2014 HOLD Buy
-11.6% avg upside
57 analysts
$121.00
64.15% Downside
 +33.4%
BCRX
BioCryst
 Feb 28, 2014 HOLD Strong Buy
+103.3% avg upside
24 analysts
 — -12.8%
GILD
Gilead Sciences
 Jan 26, 2014 BUY Strong Buy
-4.8% avg upside
66 analysts
$86.00
30.42% Downside
 +35.8%
NAVBQ
Navidea
 Nov 07, 2013 BUY Buy
+2833233.3% avg upside
4 analysts
$3.00
2999899.91% Upside
 ·
MYRX
Myrexis
 Oct 01, 2013 BUY Strong Buy
+3499900.1% avg upside
2 analysts
 — -2.2%
RGDXQ
Response Genetics
 Aug 08, 2013 BUY Strong Buy
+137499900.0% avg upside
1 analyst
$2.75
137499900.04% Upside
 ·
🔒 48 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kevin DeGeeter — Frequently Asked Questions
How accurate are Kevin DeGeeter's stock ratings?
Based on the calls 13Foresight could measure, about 35% of Kevin's ratings were profitable over a one-year hold, with an average return of -11.5% per rating, or -16.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Kevin ranked on 13Foresight?
Kevin DeGeeter is currently ranked #2536 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kevin cover?
Kevin most recently has ratings on ELTX, TRAW, CLRB, URGN, DCOY, ORIC, CRDF, NXTC, OPK, NVCR, IONS, ANTX and 41 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.